Experimental Hematology
Volume 38, Issue 4 , Pages 259-269.e2 , April 2010

Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models

  • Rachele Alzani

      Affiliations

    • Nerviano Medical Sciences Srl, Business Unit Oncology, Nerviano, Italy
    • Drs. Alzani and Pedrini contributed equally to this work.
    • ,
  • Olga Pedrini

      Affiliations

    • Laboratory of Cellular Therapy “G. Lanzani,” USC Haematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    • Drs. Alzani and Pedrini contributed equally to this work.
    • ,
  • Clara Albanese

      Affiliations

    • Nerviano Medical Sciences Srl, Business Unit Oncology, Nerviano, Italy
    • ,
  • Roberta Ceruti

      Affiliations

    • Nerviano Medical Sciences Srl, Business Unit Oncology, Nerviano, Italy
    • ,
  • Alessia Casolaro

      Affiliations

    • Nerviano Medical Sciences Srl, Business Unit Oncology, Nerviano, Italy
    • ,
  • Veronica Patton

      Affiliations

    • Nerviano Medical Sciences Srl, Business Unit Oncology, Nerviano, Italy
    • ,
  • Francesco Colotta

      Affiliations

    • Nerviano Medical Sciences Srl, Business Unit Oncology, Nerviano, Italy
    • ,
  • Alessandro Rambaldi

      Affiliations

    • Laboratory of Cellular Therapy “G. Lanzani,” USC Haematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    • ,
  • Martino Introna

      Affiliations

    • Laboratory of Cellular Therapy “G. Lanzani,” USC Haematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    • ,
  • Enrico Pesenti

      Affiliations

    • Nerviano Medical Sciences Srl, Business Unit Oncology, Nerviano, Italy
    • ,
  • Marina Ciomei

      Affiliations

    • Nerviano Medical Sciences Srl, Business Unit Oncology, Nerviano, Italy
    • ,
  • Josée Golay

      Affiliations

    • Laboratory of Cellular Therapy “G. Lanzani,” USC Haematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    • Corresponding Author InformationOffprint requests to: Josée Golay, Ph.D., Laboratory of Cellular Therapy “G. Lanzani,” Ospedali Riuniti, c/o Presidio Matteo Rota, Via Garibaldi 11-13, 24128 Bergamo, Italy

Received 13 January 2010 ,Revised 8 February 2010 ,Accepted 9 February 2010.

References 

  1. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24:1770–1783
  2. Bogner C, Sandherr M, Perker M, et al. Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells. Ann Hematol. 2006;85:458–462
  3. Ekberg J, Holm C, Jalili S, et al. Expression of cyclin A1 and cell cycle proteins in hematopoietic cells and acute myeloid leukemia and links to patient outcome. Eur J Haematol. 2005;75:106–115
  4. Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev. 2003;194:96–104
  5. Agarwal A, Bumm TG, Corbin AS, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood. 2008;112:1960–1970
  6. Deininger MW, Vieira SA, Parada Y, et al. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res. 2001;61:8005–8013
  7. Williams RT, Sherr CJ. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias. Cold Spring Harb Symp Quant Biol. 2008;73:461–467
  8. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–166
  9. Brasca MG, Albanese C, Alzani R, et al. Optimisation of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem. In press.
  10. Giavazzi R, Di Berardino C, Garofalo A, et al. Establishment of human acute myelogenous leukemia lines secreting interleukin-1 beta in SCID mice. Int J Cancer. 1995;61:280–285
  11. Golay J, Di Gaetano N, Amico D, et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br J Haematol. 2005;128:310–317
  12. Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica. 2004;89:1476–1483
  13. Radaelli E, Ceruti R, Patton V, et al. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol. 2009;24:879–891
  14. Borlado LR, Mendez J. CDC6: from DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis. 2008;29:237–243
  15. Mailand N, Diffley JF. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell. 2005;122:915–926
  16. Golay J, Cuppini L, Leoni F, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 2007;21:1892–1900
  17. Whitlock JA, Krailo M, Reid JM, et al. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2005;23:9179–9186
  18. Karp JE, Smith BD, Levis MJ, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res. 2007;13:4467–4473
  19. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399–404
  20. Fornier MN, Rathkopf D, Shah M, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res. 2007;13:5841–5846
  21. Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer. 2007;96:29–37
  22. DePinto W, Chu XJ, Yin X, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther. 2006;5:2644–2658
  23. Misra RN, Xiao HY, Kim KS, et al. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem. 2004;47:1719–1728
  24. Bettayeb K, Oumata N, Echalier A, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008;27:5797–5807
  25. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547–566
  26. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of CD133 on leukemia initiating cells in childhood ALL. Blood. 2009;113:3287–3296
  27. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood. 2007;109:674–682
  28. Terpstra W, Prins A, Ploemacher RE, et al. Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia. Blood. 1996;87:2187–2194
  29. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(−)/HLA-DR. Blood. 1998;92:4325–4335
  30. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009;458:776–779
  31. Mayani H, Flores-Figueroa E, Chavez-Gonzalez A. In vitro biology of human myeloid leukemia. Leuk Res. 2009;33:624–637
  32. Tarapore P, Shinmura K, Suzuki H, et al. Thr199 phosphorylation targets nucleophosmin to nuclear speckles and represses pre-mRNA processing. FEBS Lett. 2006;580:399–409
  33. Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 2000;103:127–140
  34. Raje N, Kumar S, Hideshima T, et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 2005;106:1042–1047
  35. MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 2005;65:5399–5407
  36. Joshi KS, Rathos MJ, Mahajan P, et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007;6:926–934
  37. Gruber F, Mustjoki S, Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2009;145:581–597

 This article is dedicated to the memory of our colleague, Valter Croci.

PII: S0301-472X(10)00048-2

doi: 10.1016/j.exphem.2010.02.004

Experimental Hematology
Volume 38, Issue 4 , Pages 259-269.e2 , April 2010

Article Tools

* Image Usage & Resolution